The United States has hit rough waters of late. Few analysts label the troubles as self-invited while others foresee a revolution. Rising trade war tensions between the United States and China are showing no signs of abatement. The issue has escalated to a point where imposition of tariffs and retaliatory tariffs may go up to $450 billion on both the sides.
Moreover, President Trump’s mulling over a restriction for Chinese companies when it comes to investing in U.S. tech firms to avert technology export is likely to worsen the scenario. If this wasn’t enough, the United States is urging countries to stop importing oil from Iran by November, raising supply-related concerns.
Furthermore, Trump’s decision to impose tariffs on steel and aluminum imported from China, the European Union, Mexico and Canada along with threats of higher tariffs for imported cars and auto parts have raised concerns.
MedTech on Stable Ground
In the wake of such a rocky scenario, investors are consistently on the lookout for safer sectors. With tailwinds like favorable consumer behavior, growing demand for liquid biopsy tests along with deferred implementation of an industry-wide Medical Device tax backing the sector, the medical device space seems to be safer territory. Per Emergo, the U.S. Medical Device industry is likely to be worth $173 billion by 2019.
Minimally-Invasive Surgical Device Market Hogs Limelight
For investors trying to pick a sub-industry with booming prospects, the minimally-invasive surgical device market is the final stop.
Reduced stay at hospital, lower healthcare costs, and pain, scaring and tissue-damage are certain benefits of opting for minimally-invasive surgery over the traditional process.
Persistence Market Research estimates the global minimally-invasive surgical device market to value around $18,900 million in 2022, at a CAGR of 6.8% between 2017 and 2022. Per a report by Mordor intelligence, the U.S. minimally invasive surgery device market is projected to see a CAGR of 8.65% between 2018 and 2023.
